Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
John Oyler
Pharma
BeiGene's Brukinsa surpasses AZ’s Calquence in quarterly sales
CEO John Oyler compared BeiGene's potential in CLL to two other legendary Big Biotech stories—Gilead in HIV and Vertex in cystic fibrosis.
Angus Liu
Feb 27, 2025 10:56am
BeiGene CEO eyes biologics deals for new US hub
Jul 24, 2024 11:40am
BeiGene doubles sales on Brukinsa, tislelizumab strength
Feb 27, 2023 10:56am
AZ-Daiichi, Biogen-Eisai, Hutchmed, Junshi—Fierce Pharma Asia
May 6, 2022 11:35am
BeiGene CEO Oyler collects 16% pay bump to $16.7M
May 5, 2022 2:12pm
BeiGene CEO talks flagship US site, stock delisting risk
Apr 29, 2022 7:00am
